{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T21:52:19Z","timestamp":1791150739188,"version":"4.1.0"},"reference-count":130,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T00:00:00Z","timestamp":1217548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1016\/j.ctrv.2008.02.004","type":"journal-article","created":{"date-parts":[[2008,4,18]],"date-time":"2008-04-18T16:12:35Z","timestamp":1208535155000},"page":"453-475","source":"Crossref","is-referenced-by-count":188,"title":["Exploring the anti-tumour activity of bisphosphonates in early breast cancer"],"prefix":"10.1016","volume":"34","author":[{"given":"M.C.","family":"Winter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Holen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.E.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2008.02.004_bib1","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/annonc\/mdl498","article-title":"Estimates of the cancer incidence and mortality in Europe in 2006","volume":"18","author":"Ferlay","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2008.02.004_bib2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/bjc.1987.13","article-title":"The clinical course of bone metastases from breast cancer","volume":"55","author":"Coleman","year":"1987","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2008.02.004_bib3","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2008.02.004_bib4","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2174\/0929867033368529","article-title":"In vitro and in vivo antitumor effects of bisphosphonates","volume":"10","author":"Clezardin","year":"2003","journal-title":"Curr Med Chem"},{"issue":"Suppl. 3","key":"10.1016\/j.ctrv.2008.02.004_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2005.09.002","article-title":"Anti-tumour activity of zoledronic acid","volume":"31","author":"Clezardin","year":"2005","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2008.02.004_bib6","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1038\/sj.bjc.6603661","article-title":"Meta-analysis of clodronate and breast cancer survival","volume":"96","author":"Ha","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2008.02.004_bib7","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","article-title":"Metastasis to bone: causes, consequences and therapeutic opportunities","volume":"2","author":"Mundy","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2008.02.004_bib8","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1677\/erc.0.0110207","article-title":"The role of bisphosphonates in breast and prostate cancers","volume":"11","author":"Brown","year":"2004","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ctrv.2008.02.004_bib9","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1172\/JCI118947","article-title":"Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis","volume":"98","author":"Guise","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ctrv.2008.02.004_bib10","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1572::AID-CNCR7>3.0.CO;2-M","article-title":"Parathyroid hormone-related protein and bone metastases","volume":"80","author":"Guise","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2008.02.004_bib11","first-page":"3914","article-title":"Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis","volume":"5","author":"Diel","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2008.02.004_bib12","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1210\/en.137.6.2347","article-title":"Bone sialoprotein stimulates in vitro bone resorption","volume":"137","author":"Raynal","year":"1996","journal-title":"Endocrinology"},{"key":"10.1016\/j.ctrv.2008.02.004_bib13","series-title":"Textbook of bone metastases","first-page":"51","article-title":"The role of RANK, RANK ligand and osteoprotegerin in the lytic effects and growth of bone metastases","author":"Dunstan","year":"2005"},{"key":"10.1016\/j.ctrv.2008.02.004_bib14","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1002\/cncr.21383","article-title":"Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma","volume":"104","author":"Zhou","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2008.02.004_bib15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S8756-3282(99)00116-7","article-title":"Bisphosphonates: from the laboratory to the clinic and back again","volume":"25","author":"Russell","year":"1999","journal-title":"Bone"},{"key":"10.1016\/j.ctrv.2008.02.004_bib16","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1002\/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L","article-title":"Cellular and molecular mechanisms of action of bisphosphonates","volume":"88","author":"Rogers","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2008.02.004_bib17","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J"},{"key":"10.1016\/j.ctrv.2008.02.004_bib18","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2008.02.004_bib19","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial \u2013 the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group","volume":"21","author":"Rosen","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2008.02.004_bib20","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","article-title":"Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial","volume":"23","author":"Kohno","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2008.02.004_bib21","first-page":"41S","article-title":"Zoledronate: phase I and pharmacokinetics\/pharmacodynamics study in cancer patients","volume":"26","author":"Saeki","year":"2000","journal-title":"Bone"},{"key":"10.1016\/j.ctrv.2008.02.004_bib22","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1177\/009127002762491316","article-title":"Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases","volume":"42","author":"Chen","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ctrv.2008.02.004_bib23","doi-asserted-by":"crossref","first-page":"5406","DOI":"10.1158\/1078-0432.CCR-07-0247","article-title":"Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid","volume":"13","author":"Brown","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2008.02.004_bib24","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/jbmr.5650101008","article-title":"Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo","volume":"10","author":"Hughes","year":"1995","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ctrv.2008.02.004_bib25","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S8756-3282(01)00412-4","article-title":"Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro","volume":"28","author":"Benford","year":"2001","journal-title":"Bone"},{"key":"10.1016\/j.ctrv.2008.02.004_bib26","first-page":"27","article-title":"Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix","volume":"1","author":"Boonekamp","year":"1986","journal-title":"Bone Miner"},{"key":"10.1016\/j.ctrv.2008.02.004_bib27","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/jbmr.5650030210","article-title":"Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: the effect of a bisphosphonate","volume":"3","author":"Lowik","year":"1988","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ctrv.2008.02.004_bib28","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1124\/mol.56.1.131","article-title":"Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs","volume":"56","author":"Benford","year":"1999","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.ctrv.2008.02.004_bib29","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0022-3565(24)38786-5","article-title":"Structure\u2013activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates","volume":"296","author":"Dunford","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ctrv.2008.02.004_bib30","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/cmdc.200500059","article-title":"Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs","volume":"1","author":"Rondeau","year":"2006","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ctrv.2008.02.004_bib31","doi-asserted-by":"crossref","first-page":"7829","DOI":"10.1073\/pnas.0601643103","article-title":"The molecular mechanisms of nitrogen-containing bisphosphonates as antiosteoporosis drugs","volume":"103","author":"Kavanagh","year":"2006","journal-title":"Proc Natl Acad Sci"},{"issue":"Suppl. 4","key":"10.1016\/j.ctrv.2008.02.004_bib32","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1634\/theoncologist.9-90004-3","article-title":"Bisphosphonates: preclinical review","volume":"9","author":"Green","year":"2004","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2008.02.004_bib33","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1359\/jbmr.1998.13.11.1668","article-title":"Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages","volume":"13","author":"Luckman","year":"1998","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ctrv.2008.02.004_bib34","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1359\/jbmr.1998.13.4.581","article-title":"Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras","volume":"13","author":"Luckman","year":"1998","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ctrv.2008.02.004_bib35","doi-asserted-by":"crossref","first-page":"10022","DOI":"10.1073\/pnas.0702254104","article-title":"Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases","volume":"104","author":"Guo","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ctrv.2008.02.004_bib36","doi-asserted-by":"crossref","first-page":"22004","DOI":"10.1074\/jbc.M602603200","article-title":"The crystal structure of human geranylgeranyl pyrophosphate synthase reveals a novel hexameric arrangement and inhibitory product binding","volume":"281","author":"Kavanagh","year":"2006","journal-title":"J Bio Chem"},{"key":"10.1016\/j.ctrv.2008.02.004_bib37","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/ncponc0520","article-title":"Mechanisms of disease: preclinical reports of antineoplastic synergistic action of bisphosphonates","volume":"3","author":"Santini","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.ctrv.2008.02.004_bib38","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1093\/annonc\/mdg401","article-title":"The antineoplastic role of bisphosphonates: from basic research to clinical evidence","volume":"14","author":"Santini","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2008.02.004_bib39","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S8756-3282(99)00197-0","article-title":"Ultrastructural and cytochemical studies on cell death of osteoclasts induced by bisphosphonate treatment","volume":"25","author":"Ito","year":"1999","journal-title":"Bone"},{"key":"10.1016\/j.ctrv.2008.02.004_bib40","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1359\/jbmr.060118","article-title":"Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases","volume":"21","author":"Dunford","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ctrv.2008.02.004_bib41","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.bjp.0706628","article-title":"A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates","volume":"147","author":"Monkkonen","year":"2006","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ctrv.2008.02.004_bib42","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.lfs.2007.08.007","article-title":"Zoledronic acid-induced IPP\/ApppI production in vivo","volume":"81","author":"Monkkonen","year":"2007","journal-title":"Life Sci"},{"key":"10.1016\/j.ctrv.2008.02.004_bib43","first-page":"6538","article-title":"Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats","volume":"62","author":"Fournier","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2008.02.004_bib44","first-page":"2949","article-title":"Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases","volume":"60","author":"Boissier","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2008.02.004_bib45","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1359\/jbmr.2000.15.11.2211","article-title":"Bisphosphonates induce breast cancer cell death in vitro","volume":"15","author":"Fromigue","year":"2000","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ctrv.2008.02.004_bib46","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1054\/bjoc.1999.1131","article-title":"Bisphosphonates induce apoptosis in human breast cancer cell lines","volume":"82","author":"Senaratne","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2008.02.004_bib47","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.canlet.2006.03.011","article-title":"Differential effects of bisphosphonates on breast cancer cell lines","volume":"246","author":"Verdijk","year":"2007","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ctrv.2008.02.004_bib48","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/jpet.102.035295","article-title":"Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid","volume":"302","author":"Wood","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ctrv.2008.02.004_bib49","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/sj.bjc.6600297","article-title":"The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells","volume":"86","author":"Senaratne","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2008.02.004_bib50","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-03-0325","article-title":"Zoledronic acid inhibits visceral metastases in the 4T1\/luc mouse breast cancer model","volume":"10","author":"Hiraga","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2008.02.004_bib51","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1054\/bjoc.2001.1727","article-title":"The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel","volume":"84","author":"Jagdev","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2008.02.004_bib52","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1097\/00000421-200212001-00006","article-title":"Future directions in the treatment and prevention of bone metastases","volume":"25","author":"Coleman","year":"2002","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ctrv.2008.02.004_bib53","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/sj.bjc.6601009","article-title":"Bisphosphonates antagonise bone growth factors\u2019 effects on human breast cancer cells survival","volume":"89","author":"Fromigue","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2008.02.004_bib54","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/sj.bjc.6600925","article-title":"New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects","volume":"88","author":"Denoyelle","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2008.02.004_bib55","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2003-05-1655","article-title":"Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo","volume":"102","author":"Dieli","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2008.02.004_bib56","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood.V96.2.384","article-title":"Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma","volume":"96","author":"Kunzmann","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2008.02.004_bib57","first-page":"3890","article-title":"Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices","volume":"57","author":"Boissier","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2008.02.004_bib58","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1172\/JCI118841","article-title":"Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro","volume":"98","author":"van der Pluijm","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ctrv.2008.02.004_bib59","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1158\/0008-5472.CAN-05-0264","article-title":"Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity","volume":"65","author":"Clezardin","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2008.02.004_bib60","doi-asserted-by":"crossref","first-page":"7212","DOI":"10.1200\/JCO.2005.07.501","article-title":"Proliferation marker Ki-67 in early breast cancer","volume":"23","author":"Urruticoechea","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2008.02.004_bib61","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1136\/bmj.322.7301.1536","article-title":"What is apoptosis, and why is it important?","volume":"322","author":"Renehan","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.ctrv.2008.02.004_bib62","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/ijc.20602","article-title":"Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells","volume":"113","author":"Neville-Webbe","year":"2005","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2008.02.004_bib63","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000092489","article-title":"Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro","volume":"27","author":"Neville-Webbe","year":"2006","journal-title":"Tumour Biol"},{"key":"10.1016\/j.ctrv.2008.02.004_bib64","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1677\/erc.1.01094","article-title":"Emerging anti-cancer molecular mechanisms of aminobisphosphonates","volume":"13","author":"Caraglia","year":"2006","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ctrv.2008.02.004_bib65","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/8756-3282(95)00445-9","article-title":"Bisphosphonates: a review of their pharmacokinetic properties","volume":"18","author":"Lin","year":"1996","journal-title":"Bone"},{"key":"10.1016\/j.ctrv.2008.02.004_bib66","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1177\/0091270002239824","article-title":"The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function","volume":"43","author":"Skerjanec","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ctrv.2008.02.004_bib67","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1172\/JCI115539","article-title":"Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure","volume":"88","author":"Sato","year":"1991","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ctrv.2008.02.004_bib68","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10549-005-9067-x","article-title":"From genetic abnormality to metastases; murine models of breast cancer and their use in the development of anticancer therapies","volume":"96","author":"Ottewell","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2008.02.004_bib69","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/1097-0142(19930701)72:1<91::AID-CNCR2820720118>3.0.CO;2-2","article-title":"Prophylactic treatment of skeletal metastases, tumor-induced osteolysis, and hypercalcemia in rats with the bisphosphonate Cl2MBP","volume":"72","author":"Krempien","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2008.02.004_bib70","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000226528","article-title":"Protective effects of a prophylactic treatment with the bisphosphonate 3-amino-1-hydroxypropane-1,1-bisphosphonic acid on the development of tumor osteopathies in the rat: experimental studies with the Walker carcinosarcoma 256","volume":"45","author":"Krempien","year":"1988","journal-title":"Oncology"},{"key":"10.1016\/j.ctrv.2008.02.004_bib71","first-page":"3551","article-title":"Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice","volume":"55","author":"Sasaki","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2008.02.004_bib72","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/(SICI)1097-0215(19980717)77:2<279::AID-IJC18>3.0.CO;2-6","article-title":"Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice","volume":"77","author":"Sasaki","year":"1998","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2008.02.004_bib73","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1002\/1097-0142(20000615)88:12+<2979::AID-CNCR13>3.0.CO;2-U","article-title":"Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma","volume":"88","author":"Yoneda","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2008.02.004_bib74","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0093-7754(01)90263-5","article-title":"Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment","volume":"28","author":"Mundy","year":"2001","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ctrv.2008.02.004_bib75","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1023\/A:1019905111666","article-title":"The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs","volume":"75","author":"Michigami","year":"2002","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2008.02.004_bib76","first-page":"4418","article-title":"The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases","volume":"61","author":"Hiraga","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2008.02.004_bib77","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/jnci\/djk054","article-title":"Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis","volume":"99","author":"Daubine","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2008.02.004_bib78","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2008.02.004_bib79","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1200\/JCO.2001.19.4.1207","article-title":"Clinical implications of circulating angiogenic factors in cancer patients","volume":"19","author":"Poon","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2008.02.004_bib80","doi-asserted-by":"crossref","first-page":"43603","DOI":"10.1074\/jbc.M308114200","article-title":"Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B\/Akt","volume":"278","author":"Bezzi","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ctrv.2008.02.004_bib81","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/sj.bjc.6603740","article-title":"Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer","volume":"96","author":"Duivenvoorden","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2008.02.004_bib82","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/ijc.11330","article-title":"Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1\/luc mouse breast cancer","volume":"106","author":"Hiraga","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2008.02.004_bib83","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1677\/erc.1.01061","article-title":"Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer","volume":"12","author":"Melisi","year":"2005","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ctrv.2008.02.004_bib84","first-page":"S28","article-title":"Understanding drug-sequence-dependent synergistic induction of apoptosis by zoledronic acid (zol) and doxorubicin (dox) in breast cancer","volume":"31","author":"Neville-Webbe","year":"2005","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2008.02.004_bib85","doi-asserted-by":"crossref","unstructured":"Ottewell PD, Deux B, Monkkonen H, et al. Differential effects of doxorubicin and zoledronic acid on intra-osscous vs extraosseous bresat tumour growth in vivo. Clin Cancer Res. 2008 (in press).","DOI":"10.1158\/1078-0432.CCR-07-1545"},{"key":"10.1016\/j.ctrv.2008.02.004_bib86","doi-asserted-by":"crossref","unstructured":"Ottewell PD, Jones M, Coleman RE, Holen I. Synergistic effects of cytotoxic drugs and anti-retrospective agents in vitro and in vivo. In: 29th annual San Antonio breast cancer symposium, vol. 100 (Suppl. 1); 2006 [abstract 6102].","DOI":"10.1186\/bcr1591"},{"key":"10.1016\/j.ctrv.2008.02.004_bib87","doi-asserted-by":"crossref","first-page":"R52","DOI":"10.1186\/bcr1543","article-title":"In vitro synergistic cytoreductive effects of zoledronic acid and radiation on breast cancer cells","volume":"8","author":"Ural","year":"2006","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ctrv.2008.02.004_bib88","first-page":"1109","article-title":"Breast tumour growth inhibition in vitro through the combination of cyclophosphamide\/metotrexate\/5-fluorouracil, epirubicin\/cyclophosphamide, epirubicin\/paclitaxel, and epirubicin\/docetaxel with the bisphosphonates ibandronate and zoledronic acid","volume":"12","author":"Vogt","year":"2004","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ctrv.2008.02.004_bib89","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1097\/01.COC.0000074165.90133.40","article-title":"Effect of the combination of docetaxel, zoledronic acid, and a COX-2 inhibitor on the growth of human breast cancer cell lines","volume":"26","author":"Witters","year":"2003","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ctrv.2008.02.004_bib90","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1097\/01.cad.0000175582.01446.6f","article-title":"Combined effects of zoledronic acid and doxorubicin on breast cancer cell invasion in vitro","volume":"16","author":"Woodward","year":"2005","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ctrv.2008.02.004_bib91","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/(SICI)1097-0215(19991008)83:2<263::AID-IJC19>3.0.CO;2-T","article-title":"Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone","volume":"83","author":"Magnetto","year":"1999","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2008.02.004_bib92","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJM199808063390601","article-title":"Reduction in new metastases in breast cancer with adjuvant clodronate treatment","volume":"339","author":"Diel","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2008.02.004_bib93","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1200\/JCO.2002.11.080","article-title":"Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer","volume":"20","author":"Powles","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2008.02.004_bib94","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1200\/JCO.2001.19.1.10","article-title":"Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial","volume":"19","author":"Saarto","year":"2001","journal-title":"J Clin Oncol"},{"issue":"16 Suppl.","key":"10.1016\/j.ctrv.2008.02.004_bib95","first-page":"99s","article-title":"Pamidronate as adjuvant treatment for prevention of bone metastases in breast cancer","volume":"23","author":"Jung","year":"2005","journal-title":"J Clin Oncol"},{"issue":"14 Suppl.","key":"10.1016\/j.ctrv.2008.02.004_bib96","first-page":"9","article-title":"Adjuvant pamidronate (PMT) therapy for the prevention of bone metastases in breast cancer (BC) patients with four or more positive nodes","volume":"22","author":"Kokufu","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2008.02.004_bib97","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S8756-3282(96)00285-2","article-title":"Clodronate decreases the frequency of skeletal metastases in women with breast cancer","volume":"19","author":"Kanis","year":"1996","journal-title":"Bone"},{"key":"10.1016\/j.ctrv.2008.02.004_bib98","first-page":"109","article-title":"Oral pamidronate in the prevention and treatment of skeletal metastases in patients with breast cancer","volume":"57","author":"van Holten-Verzantvoort","year":"1997","journal-title":"Medicina (B Aires)"},{"key":"10.1016\/j.ctrv.2008.02.004_bib99","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1200\/JCO.1992.10.10.1534","article-title":"Detection of tumor cells in bone marrow of patients with primary breast cancer: a prognostic factor for distant metastasis","volume":"10","author":"Diel","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2008.02.004_bib100","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1056\/NEJMoa050434","article-title":"A pooled analysis of bone marrow micrometastasis in breast cancer","volume":"353","author":"Braun","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2008.02.004_bib101","article-title":"Bisphosphonates in the reduction of metastases in breast cancer \u2013 results of the extended follow-up of the first study population (abstract)","volume":"82a","author":"Diel","year":"2000","journal-title":"Proc ASCO"},{"key":"10.1016\/j.ctrv.2008.02.004_bib102","doi-asserted-by":"crossref","unstructured":"Jaschke A, Bastert G, Solomayer EF, et al. Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow \u2013 a longtime follow-up. In: ASCO annual meeting proceedings (post-meeting edition), vol. 22 (no. 14S); 2004. p. 529.","DOI":"10.1200\/jco.2004.22.90140.529"},{"key":"10.1016\/j.ctrv.2008.02.004_bib103","doi-asserted-by":"crossref","unstructured":"Saarto T, Vehmanen L, Blomqvist C, Elomaa I. Ten-year follow-up of a randomised controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. In: 2004 ASCO annual meeting proceedings. J Clin Oncol 2004;22 (no.14S):527.","DOI":"10.1200\/jco.2004.22.14_suppl.527"},{"key":"10.1016\/j.ctrv.2008.02.004_bib104","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1186\/bcr1384","article-title":"Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]","volume":"8","author":"Powles","year":"2006","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ctrv.2008.02.004_bib105","doi-asserted-by":"crossref","unstructured":"Lin A, Park J, Melisko M, et al. Zoledronic acid as adjuvant therapy for women with early stage breast cancer and occult tumor cells in bone marrow. In 30th annual San Antonio breast cancer symposium; 2007 [abstract 510].","DOI":"10.1016\/S1359-6349(08)70558-5"},{"key":"10.1016\/j.ctrv.2008.02.004_bib106","unstructured":"Rack BK, Jueckstock J, Genss E-M, et al. Effect of zoledronate on persisting isolated tumor cells in the bone marrow of patients without recurrence of early breast cancer. In: 30th annual San Antonio breast cancer symposium; 2007 [abstract 511]."},{"key":"10.1016\/j.ctrv.2008.02.004_bib107","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000087286","article-title":"Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients","volume":"69","author":"Ferretti","year":"2005","journal-title":"Oncology"},{"key":"10.1016\/j.ctrv.2008.02.004_bib108","first-page":"1080","article-title":"Pamidronate induces modifications of circulating angiogenetic factors in cancer patients","volume":"8","author":"Santini","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2008.02.004_bib109","first-page":"2893","article-title":"Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients","volume":"9","author":"Santini","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2008.02.004_bib110","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1749-6632.1992.tb51603.x","article-title":"Vascular permeability factor, fibrin, and the pathogenesis of tumor stroma formation","volume":"667","author":"Dvorak","year":"1992","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ctrv.2008.02.004_bib111","first-page":"1351","article-title":"Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours","volume":"15","author":"Santini","year":"2006","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ctrv.2008.02.004_bib112","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1158\/1078-0432.CCR-07-0551","article-title":"Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients","volume":"13","author":"Santini","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2008.02.004_bib113","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1677\/erc.0.0090183","article-title":"The biology of neoadjuvant chemotherapy for breast cancer","volume":"9","author":"Cleator","year":"2002","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ctrv.2008.02.004_bib114","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1136\/jcp.51.10.716","article-title":"Proliferation markers in tumours: interpretation and clinical value","volume":"51","author":"van Diest","year":"1998","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.ctrv.2008.02.004_bib115","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1083\/jcb.119.3.493","article-title":"Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation","volume":"119","author":"Gavrieli","year":"1992","journal-title":"J Cell Biol"},{"key":"10.1016\/j.ctrv.2008.02.004_bib116","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1136\/jcp.2003.010777","article-title":"Prognostic value of proliferation in invasive breast cancer: a review","volume":"57","author":"van Diest","year":"2004","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.ctrv.2008.02.004_bib117","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/ijc.2910570610","article-title":"Cell kinetics in human breast cancer: comparison between the prognostic value of the cytofluorimetric S-phase fraction and that of the antibodies to Ki-67 and PCNA antigens detected by immunocytochemistry","volume":"57","author":"Gasparini","year":"1994","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2008.02.004_bib118","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/cncr.10458","article-title":"Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value","volume":"94","author":"Spyratos","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2008.02.004_bib119","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1200\/JCO.1999.17.2.470","article-title":"Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer","volume":"17","author":"Thor","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2008.02.004_bib120","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1200\/JCO.1998.16.8.2672","article-title":"Effect of preoperative chemotherapy on the outcome of women with operable breast cancer","volume":"16","author":"Fisher","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2008.02.004_bib121","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.1200\/JCO.2001.19.22.4224","article-title":"Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902","volume":"19","author":"van der Hage","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2008.02.004_bib122","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1023\/A:1005933815809","article-title":"Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy","volume":"48","author":"Ellis","year":"1998","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2008.02.004_bib123","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/sj.bjc.6601173","article-title":"Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer","volume":"89","author":"Archer","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2008.02.004_bib124","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(05)61752-7","article-title":"Preoperative chemotherapy induces apoptosis in early breast cancer","volume":"349","author":"Ellis","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2008.02.004_bib125","unstructured":"Archer C, Salter J, Hills M, Dowsett M, Smith IE. Induction of apoptosis and reduction in proliferation 24 hours after primary chemotherapy in early breast cancer. In: Proceedings of the American society of clinical oncologists; 1999 [abstract 308]."},{"key":"10.1016\/j.ctrv.2008.02.004_bib126","first-page":"955","article-title":"Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response","volume":"9","author":"Davis","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2008.02.004_bib127","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1200\/JCO.1999.17.10.3058","article-title":"Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer","volume":"17","author":"Chang","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2008.02.004_bib128","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1002\/1097-0142(20001201)89:11<2145::AID-CNCR1>3.0.CO;2-S","article-title":"Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma","volume":"89","author":"Chang","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2008.02.004_bib129","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1023\/B:BREA.0000003968.45511.3f","article-title":"Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer","volume":"82","author":"Assersohn","year":"2003","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2008.02.004_bib130","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1186\/bcr1508","article-title":"Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer","volume":"8","author":"Burcombe","year":"2006","journal-title":"Breast Cancer Res"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737208000431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737208000431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T20:13:43Z","timestamp":1738181623000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737208000431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8]]},"references-count":130,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["S0305737208000431"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2008.02.004","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2008,8]]}}}